文献速递流行病学与生物统计临床试验与 GCP

高危型人乳头瘤病毒检测筛查宫颈癌:USPSTF更新证据报告与系统综述

Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2018-01-01

本系统综述纳入8项随机临床试验(n=410 556)、5项队列研究(n=402 615)和1项个体参与者数据荟萃分析(n=176 464),评估以高危型人乳头瘤病毒(hrHPV)检测为主的筛查与细胞学筛查相比的获益与危害。结果显示,初次hrHPV筛查在第一轮可检出更多CIN 3及以上病变,但假阳性和阴道镜检查率均高于细胞学筛查;任何hrHPV筛查策略相比单纯细胞学筛查与侵袭性宫颈癌风险降低相关(合并RR 0.60,95%CI 0.40-0.89)。

要点

  • 初次hrHPV筛查第一轮CIN 3+检出率高于细胞学,但假阳性与阴道镜检查率也更高。
  • hrHPV联合检测第一轮CIN 3+检出与细胞学无显著差异,两轮累积RR为0.91至1.13。
  • 任何hrHPV筛查相比单纯细胞学与侵袭性宫颈癌风险降低相关(合并RR 0.60)。

核心结论

  • 与细胞学筛查相比,初次hrHPV筛查在第一轮检出更高的CIN 3+率,但假阳性和阴道镜检查率更高,可能导致更多治疗及潜在危害。
  • 任何hrHPV筛查策略相比单纯细胞学筛查与侵袭性宫颈癌风险降低相关(合并RR 0.60,95%CI 0.40-0.89)。

研究设计与样本

  • 系统综述纳入8项随机临床试验(n=410 556)、5项队列研究(n=402 615)和1项个体参与者数据荟萃分析(n=176 464)。
  • 检索MEDLINE、PubMed、PsycINFO和Cochrane对照试验注册库,时间自2011年1月至2017年2月15日,监测至2018年5月25日。
  • 纳入比较单纯hrHPV初筛或hrHPV联合检测(hrHPV检测联合细胞学)与单纯细胞学(巴氏涂片)筛查的随机临床试验和队列研究。
  • 由两名研究者独立审阅摘要和全文并对纳入研究进行质量评级,数据采用定性综合。

主要发现

  • 4项试验一致显示初次hrHPV筛查第一轮CIN 3+检出增加(RR范围1.61[95%CI 1.09-2.37]至7.46[95%CI 1.02-54.66])。
  • 4项hrHPV联合检测试验第一轮CIN 3+检出在筛查组间无显著差异,两轮筛查累积CIN 3+检出的RR范围为0.91至1.13。
  • 第一轮筛查中,初次hrHPV筛查假阳性率为6.6%至7.4%,细胞学为2.6%至6.5%;联合检测假阳性率为5.8%至19.9%,细胞学为2.6%至10.9%。
  • 第一轮阴道镜检查率:初次hrHPV检测为1.2%至7.9%,单纯细胞学为1.1%至3.1%;联合检测为6.8%至10.9%,单纯细胞学为3.3%至5.2%。

关键数值与推荐

  • 初次hrHPV筛查第一轮CIN 3+检出RR范围为1.61(95%CI 1.09-2.37)至7.46(95%CI 1.02-54.66)。
  • hrHPV联合检测两轮筛查累积CIN 3+检出RR范围为0.91至1.13。
  • 任何hrHPV筛查相比单纯细胞学筛查,侵袭性宫颈癌合并RR为0.60(95%CI 0.40-0.89)。
  • 初次hrHPV筛查第一轮假阳性率6.6%至7.4%,联合检测5.8%至19.9%,细胞学2.6%至10.9%。

临床怎么用

  • hrHPV筛查可提高第一轮CIN 3+检出并降低侵袭性宫颈癌风险,但需权衡更高的假阳性与阴道镜检查率。
  • 临床选择筛查策略时应考虑假阳性及相关后续检查、治疗带来的潜在危害。
  • 试验在筛查间隔、轮次和方案上存在异质性,应用证据时需结合具体筛查方案。

局限性

  • 纳入试验在筛查间隔、筛查轮次和方案方面存在异质性。
  • 数据采用定性综合,未进行定量合并(除引用IPD荟萃分析外)。
  • 部分RR的95%CI较宽,如7.46(95%CI 1.02-54.66),估计精度有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Cervical cancer can be prevented with detection and treatment of precancerous cell changes caused primarily by high-risk types of human papillomavirus (hrHPV), the causative agents in more than 90% of cervical cancers. OBJECTIVE: To systematically review benefits and harms of cervical cancer screening for hrHPV to inform the US Preventive Services Task Force. DATA SOURCES: MEDLINE, PubMed, PsycINFO, and the Cochrane Collaboration Registry of Controlled Trials from January 2011 through February 15, 2017; surveillance through May 25, 2018. STUDY SELECTION: Randomized clinical trials (RCTs) and cohort studies comparing primary hrHPV screening alone or hrHPV cotesting (both hrHPV testing and cytology) with cytology (Papanicolaou [Pap] test) screening alone. DATA EXTRACTION AND SYNTHESIS: Two investigators independently reviewed abstracts and full-text articles and quality rated included studies; data were qualitatively synthesized. MAIN OUTCOMES AND MEASURES: Invasive cervical cancer; cervical intraepithelial neoplasia (CIN); false-positive, colposcopy, and biopsy rates; psychological harms. RESULTS: Eight RCTs (n = 410 556), 5 cohort studies (n = 402 615), and 1 individual participant data (IPD) meta-analysis (n = 176 464) were included. Trials were heterogeneous for screening interval, number of rounds, and protocol. For primary hrHPV screening, evidence was consistent across 4 trials demonstrating increased detection of CIN 3 or worse (CIN 3+) in round 1 (relative risk [RR] range, 1.61 [95% CI, 1.09-2.37] to 7.46 [95% CI, 1.02-54.66]). Among 4 hrHPV cotesting trials, first-round CIN 3+ detection was not significantly different between screening groups; RRs for cumulative CIN 3+ detection over 2 screening rounds ranged from 0.91 to 1.13. In first-round screening, false-positive rates for primary hrHPV screening ranged from 6.6% to 7.4%, compared with 2.6% to 6.5% for cytology. For cotesting, false-positives ranged from 5.8% to 19.9% in the first round of screening, compared with 2.6% to 10.9% for cytology. First-round colposcopy rates were also higher, ranging 1.2% to 7.9% for primary hrHPV testing, compared with 1.1% to 3.1% for cytology alone; colposcopy rates for cotesting ranged from 6.8% to 10.9%, compared with 3.3% to 5.2% for cytology alone. The IPD meta-analysis of data from 4 cotesting trials and 1 primary hrHPV screening trial found lower risk of invasive cervical cancer with any hrHPV screening compared with cytology alone (pooled RR, 0.60 [95% CI, 0.40-0.89]). CONCLUSIONS AND RELEVANCE: Primary hrHPV screening detected higher rates of CIN 3+ at first-round screening compared with cytology. Cotesting trials did not show initial increased CIN 3+ detection. Both hrHPV screening strategies had higher false-positive and colposcopy rates than cytology, which could lead to more treatments with potential harms.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Melnikow J, Henderson JT, Burda BU, et al. Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018. PMID: 30140883. doi:10.1001/jama.2018.10400

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。